Traws Pharma shares surge 53.11% intraday after reporting Q3 cost cuts and antiviral drug trial progress.

Traws Pharma surged 53.11% intraday following the release of its Q3 2025 financial results, which highlighted significant cost reductions, the acquisition of intellectual property, and advancements in Phase 2 trials for antiviral therapies targeting COVID-19, bird flu, and seasonal flu. The company also reported a narrower net loss year-over-year and a strategic pivot toward antiviral programs and partnerships for legacy oncology assets. These developments, coupled with a recent analyst "Buy" rating and a $6.00 price target, likely drove investor optimism despite bearish technical indicators and a low overall stock score. The announcement underscored the company’s focus on high-potential markets and operational efficiency, aligning with the sharp intraday rally.